Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Dr. Ashish Kamat Interview - BOND-003 Study Results

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Jan 09, 2024 7:20pm

207 Views

Post# 35818436

RE:RE:RE:RE:RE:RE:RE:Dr. Ashish Kamat Interview - BOND-003 Study Results

Ruvidar by far given the much lower frequency of treatments 1-3 Vs many more for up to 2-3 years. Virtually same efficacy.

Gman620 wrote: Seems like they got a good sized study population pulled together pretty quickly.

So which study would you join if you were in that situation and had the offer from both?

<< Previous

Bullboard Posts

Next >>

Visionstate set to leverage success in the U.S. market